Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.

Afif W, Leighton JA, Hanauer SB, Loftus EV, Faubion WA, Pardi DS, Tremaine WJ, Kane SV, Bruining DH, Cohen RD, Rubin DT, Hanson KA, Sandborn WJ. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis. 2009 Sep; 15(9):1302-7.

View in: PubMed